Interleukin-36 in Infectious and Inflammatory Skin Diseases

Interleukin-36 (IL-36) comprises to a cytokine family consisting of four isoforms IL-36α, IL-36β, IL-36γ, and IL-36 receptor antagonist (IL-36 Ra). These IL-36 cytokines, in turn, belong to the IL-1 superfamily. The IL-36 receptor (IL-1R6) is functional as a heterodimer formed of IL-1R6 and IL-1 receptor accessory protein (IL-1RAcP). IL-36α, IL-36β, and IL-36γ are regarded as pro-inflammatory ligands and IL-36 Ra as well as IL-38 as anti-inflammatory ligands of IL-1R6. IL-36 cytokines are mainly expressed on the barrier sites of the body e.g., bronchial, intestinal, and dermal epithelium. One of their most important biological functions is the bridging of innate and adaptive immune responses. A disturbed balance between pro-inflammatory and anti-inflammatory branches easily leads to inflammation of the corresponding tissue. The most prominent example for an altered IL-36 expression is the spectrum of psoriasis. In addition to inflammatory dermatoses, IL-36 also seems to play a role in infectious dermatoses. Microbial triggers, especially Staphylococcus aureus infection, increase the production of pro-inflammatory IL-36 cytokines and initiate/promote the inflammation of skin lesions. Due to the discovery of IL-36 as an important immune mediator, it has already been possible to develop important diagnostic tools for dermatitis. Not only in the field of inflammatory skin diseases, but also in pulmonary and intestinal inflammation, there is evidence that IL-36 cytokines might have diagnostic and/or therapeutic relevance.

[1]  J. Seneschal,et al.  Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. , 2019, JCI insight.

[2]  M. Herbst-Kralovetz,et al.  IL‐36&ggr; induces a transient HSV‐2 resistant environment that protects against genital disease and pathogenesis , 2018, Cytokine.

[3]  T. Bieber,et al.  Candida induces the expression of IL‐36γ in human keratinocytes: implications for a pathogen‐driven exacerbation of psoriasis? , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  E. Eisenmesser,et al.  IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment , 2018, Cell Death & Disease.

[5]  S. Gaffen,et al.  IL-36 and IL-1/IL-17 Drive Immunity to Oral Candidiasis via Parallel Mechanisms , 2018, The Journal of Immunology.

[6]  S. Akira,et al.  Regnase-1, an Immunomodulator, Limits the IL-36/IL-36R Autostimulatory Loop in Keratinocytes to Suppress Skin Inflammation. , 2018, The Journal of investigative dermatology.

[7]  Seamus J. Martin,et al.  Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases , 2018, Cell Death & Disease.

[8]  L. Tsoi,et al.  RNA-Seq Analysis of IL-1B and IL-36 Responses in Epidermal Keratinocytes Identifies a Shared MyD88-Dependent Gene Signature , 2018, Front. Immunol..

[9]  L. Qing,et al.  Elevated production of IL-36α in chronic hepatitis B virus-infected patients correlates with viral load. , 2017, Microbial pathogenesis.

[10]  B. Lüscher,et al.  The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function , 2017, Scientific Reports.

[11]  G. Núñez,et al.  Staphylococcus aureus Virulent PSMα Peptides Induce Keratinocyte Alarmin Release to Orchestrate IL-17-Dependent Skin Inflammation. , 2017, Cell host & microbe.

[12]  R. Geha,et al.  Staphylococcus aureus Epicutaneous Exposure Drives Skin Inflammation via IL-36-Mediated T Cell Responses. , 2017, Cell host & microbe.

[13]  T. Tsai,et al.  Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness , 2017, Therapeutic advances in musculoskeletal disease.

[14]  F. Ciccarelli,et al.  An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target , 2017, Science Translational Medicine.

[15]  Hongzhong Jin,et al.  IL-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis , 2017, International journal of medical sciences.

[16]  L. Jensen Interleukin-36 cytokines may overcome microbial immune evasion strategies that inhibit interleukin-1 family signaling , 2017, Science Signaling.

[17]  D. Mennerich,et al.  Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies , 2017, mAbs.

[18]  S. Uppalapati,et al.  Interleukin-36β provides protection against HSV-1 infection, but does not modulate initiation of adaptive immune responses , 2017, Scientific Reports.

[19]  M. Ghannoum,et al.  The Mycobiome: Impact on Health and Disease States , 2017, Microbiology spectrum.

[20]  Seamus J. Martin,et al.  Neutrophil extracellular traps can serve as platforms for processing and activation of IL‐1 family cytokines , 2017, The FEBS journal.

[21]  R. Pawliczak,et al.  Correlation between IL36α and IL17 and Activity of the Disease in Selected Autoimmune Blistering Diseases , 2017, Mediators of inflammation.

[22]  T. Denning,et al.  IL-36γ signaling controls the induced regulatory T cell – TH9 cell balance via NFκB activation and STAT transcription factors , 2017, Mucosal Immunology.

[23]  A. Giatromanolaki,et al.  Successful response in a case of severe pustular psoriasis after interleukin‐1β inhibition , 2017, The British journal of dermatology.

[24]  Yibing Yin,et al.  Interleukin 36&agr; Attenuates Sepsis by Enhancing Antibacterial Functions of Macrophages , 2016, The Journal of infectious diseases.

[25]  D. Jarrossay,et al.  Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines. , 2016, Cytokine.

[26]  T. Standiford,et al.  IL‐36γ is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components , 2016, Journal of leukocyte biology.

[27]  M. Herbst-Kralovetz,et al.  IL-36γ Augments Host Defense and Immune Responses in Human Female Reproductive Tract Epithelial Cells , 2016, Front. Microbiol..

[28]  A. Alase,et al.  Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist , 2016, Scientific Reports.

[29]  Seamus J. Martin,et al.  Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines. , 2016, Cell reports.

[30]  O. Inatomi,et al.  Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.

[31]  S. Melgar,et al.  IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation , 2016, Mucosal Immunology.

[32]  T. Denning,et al.  Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage , 2016, The Journal of Immunology.

[33]  B. Le Goff,et al.  Distinct expression of interleukin (IL)‐36α, β and γ, their antagonist IL‐36Ra and IL‐38 in psoriasis, rheumatoid arthritis and Crohn's disease , 2015, Clinical and experimental immunology.

[34]  P. Saas,et al.  Faculty Opinions recommendation of Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage. , 2015 .

[35]  C. Gabay,et al.  The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases. , 2015, Cytokine.

[36]  D. Hashimoto,et al.  Synergistic Proinflammatory Responses by IL-17A and Toll-Like Receptor 3 in Human Airway Epithelial Cells , 2015, PloS one.

[37]  D. Mennerich,et al.  Signal Transduction and Intracellular Trafficking by the Interleukin 36 Receptor* , 2015, The Journal of Biological Chemistry.

[38]  S. Thomsen,et al.  Off‐label use of TNF‐alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients , 2015, Dermatologic therapy.

[39]  Mayte Suárez-Fariñas,et al.  RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. , 2015, The Journal of allergy and clinical immunology.

[40]  Michael Hölzel,et al.  IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions. , 2015, The Journal of investigative dermatology.

[41]  P. Barrow,et al.  IL-36α induces maturation of Th1-inducing human MDDC and synergises with IFN-γ to induce high surface expression of CD14 and CD11c. , 2015, Human immunology.

[42]  H. Mühl,et al.  Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury , 2015, Scientific Reports.

[43]  T. Torres,et al.  Nail psoriasis as a predictor of the development of psoriatic arthritis. , 2015, Actas dermo-sifiliograficas.

[44]  S. Jennings,et al.  Animal models of herpes simplex virus immunity and pathogenesis , 2014, Journal of NeuroVirology.

[45]  Z. Hajheydari,et al.  Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis , 2014, International journal of dermatology.

[46]  Fabian J Theis,et al.  Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema , 2014, Science Translational Medicine.

[47]  A. Smahi,et al.  Is it relevant to use an interleukin‐1‐inhibiting strategy for the treatment of patients with deficiency of interleukin‐36 receptor antagonist? , 2014, The British journal of dermatology.

[48]  M. Schön,et al.  Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations , 2014, The British journal of dermatology.

[49]  J. Gudjonsson,et al.  IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin , 2013, The Journal of Immunology.

[50]  D. Boraschi,et al.  The interleukin-1 receptor family. , 2013, Seminars in immunology.

[51]  M. Gresnigt,et al.  Biology of IL-36 cytokines and their role in disease. , 2013, Seminars in immunology.

[52]  N. Balato,et al.  The balance between pro‐ and anti‐inflammatory cytokines is crucial in human allergic contact dermatitis pathogenesis: the role of IL‐1 family members , 2013, Experimental dermatology.

[53]  Rui-Xing Yin,et al.  Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies. , 2013, International journal of cardiology.

[54]  A. Smahi,et al.  First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With Anakinra , 2013, Pediatrics.

[55]  A. Armstrong,et al.  Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. , 2013, Journal of the American Academy of Dermatology.

[56]  L. Joosten,et al.  The IL‐36 receptor pathway regulates Aspergillus fumigatus‐induced Th1 and Th17 responses , 2013, European journal of immunology.

[57]  H. Nakai,et al.  Mutation Analysis of the IL36RN Gene in 14 Japanese Patients with Generalized Pustular Psoriasis , 2013, Human mutation.

[58]  A. Derer,et al.  The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium , 2012, Annals of the rheumatic diseases.

[59]  S. Werner,et al.  Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. , 2012, The Journal of clinical investigation.

[60]  F. Sallusto,et al.  IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. , 2012, Blood.

[61]  H. Mühl,et al.  IL-36γ/IL-1F9, an Innate T-bet Target in Myeloid Cells* , 2012, The Journal of Biological Chemistry.

[62]  F. Niyonsaba,et al.  Interleukin-36 cytokines enhance the production of host defense peptides psoriasin and LL-37 by human keratinocytes through activation of MAPKs and NF-κB. , 2012, Journal of dermatological science.

[63]  B. Medoff,et al.  IL-36α Exerts Pro-Inflammatory Effects in the Lungs of Mice , 2012, PloS one.

[64]  J. Sims,et al.  IL-36 in psoriasis. , 2012, Current opinion in pharmacology.

[65]  K. Horiuchi,et al.  Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand–dependent terminal keratinocyte differentiation , 2012, The Journal of experimental medicine.

[66]  Li-Hua Lian,et al.  The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36γ. , 2012, The Journal of investigative dermatology.

[67]  Julia Oh,et al.  Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis , 2012, Genome research.

[68]  H. Orzechowski,et al.  S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[69]  P. Barrow,et al.  Expression of IL‐1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL‐1F8 and IL‐1F9 , 2012, European journal of immunology.

[70]  L. Joosten,et al.  IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist , 2012, Proceedings of the National Academy of Sciences.

[71]  Yijun Carrier,et al.  Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. , 2011, The Journal of investigative dermatology.

[72]  H. Dinh,et al.  IL-36R ligands are potent regulators of dendritic and T cells. , 2011, Blood.

[73]  C. Gabel,et al.  Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36α, IL-36β, and IL-36γ) or Antagonist (IL-36Ra) Activity , 2011, The Journal of Biological Chemistry.

[74]  M. Simpson,et al.  Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. , 2011, American journal of human genetics.

[75]  A. Smahi,et al.  Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.

[76]  P. Avila,et al.  Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. , 2011, American journal of respiratory cell and molecular biology.

[77]  James T. Elder,et al.  IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression , 2011, The Journal of Immunology.

[78]  L. Joosten,et al.  IL-1 family nomenclature , 2010, Nature Immunology.

[79]  A. Smahi,et al.  Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. , 2010, Annals of internal medicine.

[80]  Anna-Katharina Müller,et al.  Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis , 2010, The Journal of cell biology.

[81]  C. Gabel,et al.  Externalization of the Leaderless Cytokine IL-1F6 Occurs in Response to Lipopolysaccharide/ATP Activation of Transduced Bone Marrow Macrophages , 2009, The Journal of Immunology.

[82]  J. J. Taylor,et al.  Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide , 2009, Clinical and experimental immunology.

[83]  A. Rademaker,et al.  Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity , 2009, Pediatrics.

[84]  M. Lynch,et al.  IL‐1F5 mediates anti‐inflammatory activity in the brain through induction of IL‐4 following interaction with SIGIRR/TIR8 , 2008, Journal of neurochemistry.

[85]  H. Dinh,et al.  Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation , 2007, The Journal of experimental medicine.

[86]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[87]  J. Segre,et al.  Epidermal barrier formation and recovery in skin disorders. , 2006, The Journal of clinical investigation.

[88]  Ryan M. O’Connell,et al.  MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. , 2006, Immunity.

[89]  K. Rabe,et al.  Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. , 2005, Physiological genomics.

[90]  A. Bowcock,et al.  Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. , 2004, Trends in immunology.

[91]  J. Sims,et al.  Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activate the Pathway Leading to NF-κB and MAPKs* , 2004, Journal of Biological Chemistry.

[92]  N. Rothwell,et al.  IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells , 2003, Journal of Neuroimmunology.

[93]  J. E. Ford,et al.  A new nomenclature for IL-1-family genes. , 2001, Trends in immunology.

[94]  J. Sims,et al.  Annotating genes with potential roles in the immune system: six new members of the IL-1 family. , 2001, Trends in immunology.

[95]  R. Kastelein,et al.  Two Novel IL-1 Family Members, IL-1δ and IL-1ε, Function as an Antagonist and Agonist of NF-κB Activation Through the Orphan IL-1 Receptor-Related Protein 21 , 2001, The Journal of Immunology.

[96]  E. Christophers Psoriasis − epidemiology and clinical spectrum , 2001, Clinical and experimental dermatology.

[97]  I. Berdicevsky,et al.  Incidence of Candida in psoriasis – a study on the fungal flora of psoriatic patients , 2001, Mycoses.

[98]  J. E. Ford,et al.  Organization of the human interleukin-1 receptor antagonist gene IL1HY1 , 2000, Immunogenetics.

[99]  M. Doyle,et al.  Identification and Initial Characterization of Four Novel Members of the Interleukin-1 Family* , 2000, The Journal of Biological Chemistry.

[100]  Dirk E. Smith,et al.  Four New Members Expand the Interleukin-1 Superfamily* , 2000, The Journal of Biological Chemistry.

[101]  J. E. Ford,et al.  IL1HY1: A novel interleukin-1 receptor antagonist gene. , 1999, Biochemical and biophysical research communications.

[102]  F. Lowy Staphylococcus aureus infections. , 2009, The New England journal of medicine.

[103]  D. Greaves,et al.  The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci. , 1998, Genomics.